Floatz logo

Ntla-2001

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Intellia TherapeuticsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy cohort.

Asset / SponsorPhaseRating
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3B

Same molecule, other indications

Ntla-2001 is also rated in:

Transthyretin Amyloidosis (ATTR) With CardiomyopathyDormant
B
Indicative ·
60 / 100
View asset →
wild type ATTR amyloidosisDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →